Legal Representation
Attorney
James R Menker
USPTO Deadlines
Next Deadline
878 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-12-28)
Due Date
December 28, 2027
Grace Period Ends
June 28, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
45 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 7, 2025 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Nov 28, 2024 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB | Loading... |
| Jul 5, 2022 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Jun 10, 2022 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Jun 9, 2022 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Mar 28, 2022 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Dec 28, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Oct 24, 2021 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Oct 12, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 12, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 22, 2021 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Sep 22, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 22, 2021 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Sep 6, 2021 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 26, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 26, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 26, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 14, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 14, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 14, 2021 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| May 26, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 26, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 25, 2021 | ALIE | A | ASSIGNED TO LIE | Loading... |
| May 19, 2021 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | Loading... |
| Jan 30, 2021 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| Jan 13, 2021 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Jan 13, 2021 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| Nov 12, 2020 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | Loading... |
| Nov 12, 2020 | ALIE | A | ASSIGNED TO LIE | Loading... |
| May 28, 2020 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Apr 1, 2020 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Apr 1, 2020 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Apr 1, 2020 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
| Mar 7, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Mar 7, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 7, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Sep 28, 2019 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Sep 11, 2019 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Sep 11, 2019 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Aug 27, 2019 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Aug 26, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 24, 2019 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Aug 20, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 20, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 8, 2019 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; vaccines; adjuvants for use with vaccines; vaccine preparations; anti-inflammatories; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations for the treatment of inflammatory diseases; nucleic acid sequences for medical and veterinary purposes; diagnostic preparations for medical purposes for detecting mutation in prion genes; chemical preparations for use in DNA analysis for medical purposes; reagents for use in medical genetic testing; human vaccine preparations; pharmaceutical preparations for the treatment of cervical intraepithelial neoplasia; pharmaceutical preparations for the treatment of immune system related diseases and disorders; anti-asthmatic agents, namely, pharmaceutical preparations for the treatment of asthmatic disorders; dermatological pharmaceutical products; antibiotic preparations; biological preparations, namely, antibody fusion proteins for the treatment of cancer
Classification
International Classes
005